Betul Hatipoglu, MD
- Director, Diabetes Center, UH Cleveland Medical Center
- Professor, CWRU School of Medicine
- Mary B. Lee Chair in Adult Endocrinology, University Hospitals
- Specialty: Endocrinology
-
Location:UH Cleveland Medical Center Mather
11100 Euclid Ave
Cleveland, OH 44106
- Call: 216-844-3142
Biography: Betul Hatipoglu, MD
Certifications & Memberships
- Endocrinology, Diabetes and Metabolism - American Board of Internal Medicine
Education
Fellowship | Endocrinology
Endocrinology - University Of Illinois At Chicago Medical Center (1997 - 1999)
Residency | Internal Medicine/Chief Resident
Internal Medicine/Chief Resident - Michael Reese Hospital And Medical Center (1996 - 1997)
Residency | Internal Medicine
Internal Medicine - Michael Reese Hospital And Medical Center (1993 - 1996)
Medical Education
Istanbul University School Of Medicine (1992)
About
Betul Hatipoglu, MD, is the Medical Director of the Diabetes & Metabolic Care Center, and the Mary B. Lee Chair in Adult Endocrinology at University Hospitals Cleveland Medical Center since 2020. She is also a Professor of Medicine at Case Western Reserve University School of Medicine and Vice Chair at UH System Clinical Affairs.
Prior to her appointment at University Hospitals, she was a staff endocrinologist at the Cleveland Clinic for over 10 years. Dr. Hatipoglu was an Assistant Professor of Medicine and the Medical Director for the Pancreas and Islet Cell Transplant Program at the University of Illinois at Chicago for nearly eight years prior. Her clinical interests include cardiovascular disease in diabetes and population health. She received numerous excellence in teaching awards from different institutions and mentorship awards. Her research interests are in autologous islet cell transplant in chronic pancreatitis patients and new treatment modalities in type 1 diabetes and management of diabetes in population health.
Research & Publications
Research Links
PubMed
View Research
Research Interests
autologous islet cell transplant in chronic pancreatitis patients | new treatment modalities in type 1 diabetes | management of diabetes in population health
Featured Videos
Watch to find out more about this University Hospitals provider.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Betul Hatipoglu did not disclose any Outside Relationships with Industry.